{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-381060","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-09-03T11:50:15+00:00","discovered_at":"2026-09-03T11:55:01.498765+00:00","generated_at":"2026-09-03T11:55:09.876578+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Climb Bio reports positive CLYM116 Phase 1 data: ~29-day half-life, >90% APRIL suppression, Q12W dosing support","bullets":["CLYM116 half-life ~29 days, 3x longer than sibeprenlimab; >90% free APRIL suppression after single 320 mg dose.","Single 320 mg dose drove 60-75% suppression of IgA, Gd-IgA1, and IgM, maintained through 12 weeks.","No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia in 46-subject Phase 1 trial.","Phase 2 NAVIGATE-2 (800 mg load, 400 mg Q8W/Q12W) ongoing; initial data expected H1 2027; Phase 3 initiation in 2027.","High-concentration 200 mg/mL formulation enables 400 mg single SC injection; pre-filled syringe complete; autoinjector in development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-381060","json":"https://secwatch.observer/filing/0001193125-26-381060.json","markdown":"https://secwatch.observer/filing/0001193125-26-381060.md","text":"https://secwatch.observer/filing/0001193125-26-381060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/0001193125-26-381060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T11:55:09.876578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}